Novo Nordisk Just Paid $1.4B for a Chemistry Trick Most Pharma Gave Up On
Novo Nordisk just committed up to $1.4 billion to a tiny Danish biotech working on ring-shaped molecules most pharma companies gave up on. The bet: turning injectable blockbusters into pills could reshape cardiometabolic medicine, and Orbis Medicines claims to have cracked the chemistry.
The Needle Problem
Nobody loves needles. Not patients, not doctors, not the insurance companies paying for nurse visits. And yet, some of the most important drugs in cardiometabolic medicine still require an injection. Novo Nordisk built an empire on injectable semaglutide (sold as Ozempic and Wegovy), but the company clearly sees the writing on the wall: the future of chronic disease treatment is oral.
That's why Novo just signed a deal worth up to $1.4 billion with a small Danish biotech called Orbis Medicines. The target? A class of molecules called macrocycles that could turn injectable blockbusters into pills you swallow with your morning coffee.
What Orbis Actually Does
Orbis Medicines, founded in 2021, is built around a deceptively simple idea: make ring-shaped molecules that act like biologics but absorb like small-molecule drugs.
Quick chemistry detour. Biologics (think: antibodies, peptides) are great at hitting tricky disease targets. But they're big, floppy molecules that get destroyed in your gut, which is why most of them need to be injected. Small molecules (think: aspirin) survive the gut just fine, but they can't always reach the same targets. Macrocycles sit in between: they're ring-shaped compounds large enough to grab biologic-like targets, yet structured enough to potentially survive oral delivery.
The problem is that "potentially" has been doing a lot of heavy lifting in that sentence for decades. Making macrocycles that actually absorb well when swallowed is notoriously difficult. Most end up with oral bioavailability (the fraction of drug that reaches your bloodstream) in the low single digits or worse.
Orbis claims its nGen platform, which uses AI-enabled, high-throughput chemistry, has generated macrocycle candidates with preclinical oral bioavailability of up to 18%. For context, Merck's MK-0616, the most advanced oral macrocyclic peptide in clinical development, relies on a permeation enhancer and achieves roughly 2% oral bioavailability. Orbis's numbers are preclinical and unproven in humans, but they caught Novo's attention.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Follow the Money
The deal structure is a classic big-pharma optionality play. Orbis can receive up to $1.4 billion in upfront, development, and commercial milestone payments, plus tiered royalties on any future product sales. Novo is also making a strategic equity investment in Orbis, though neither company disclosed the size.
What they didn't share is just as telling. No upfront payment amount. No milestone breakdown. No specific disease targets. This level of secrecy suggests the collaboration is broad and early-stage, covering multiple programs across the cardiometabolic space rather than a single drug candidate.
Notably, this is Orbis's first major pharma partnership. For a company spun out of Novo Holdings' own seed investment arm, the deal reads like a graduation ceremony: the parent ecosystem is betting real money that the science works.
Why Novo Is Shopping Like It's Black Friday
The Orbis deal doesn't exist in a vacuum. Novo Nordisk has been on a licensing spree in 2025 and 2026 that borders on compulsive. Consider the pattern:
Lexicon's LX9851: an oral obesity candidate, licensed for up to $1 billion in March 2025.
United Laboratories' UBT251: a triple-agonist obesity therapy, secured globally for up to $2 billion (with $200 million upfront).
Vivtex: an oral peptide and protein therapy partnership reportedly worth up to $2.1 billion.
Gensaic: a cardiometabolic collaboration worth up to $354 million per target in milestones.
Add Orbis to the list and you're looking at a company that has committed billions in potential payouts to external partners in roughly 18 months. The message is unmistakable: Novo's internal R&D engine alone isn't fast enough to build the oral cardiometabolic franchise it wants.
The Bigger Strategic Bet
Novo already has an oral semaglutide product. The 25 mg Wegovy pill launched in early 2026 for weight management and cardiovascular risk reduction. Its next-generation candidate, amycretin, entered Phase 3 development in 2026 and promises even stronger weight loss. A separate deal with Septerna added four oral programs targeting GLP-1, GIP, and glucagon receptors.
So why does Novo need macrocycles too? Because GLP-1 drugs, no matter how effective, only hit one pathway. The cardiometabolic market encompasses heart failure, lipid disorders, metabolic liver disease, and conditions that GLP-1 agonists barely touch. Macrocycles could theoretically reach targets that neither traditional small molecules nor oral peptides can address, opening doors to entirely new drug classes.
Think of it like a restaurant expanding its menu. Semaglutide is the signature dish that put Novo on the map. But to become a full-service franchise, they need appetizers, sides, and desserts. Macrocycles are the new kitchen equipment that could make all of those possible.
The Competitive Landscape Is Heating Up
Novo isn't the only one who sees the opportunity. Merck's MK-0616 (enlicitide), an oral macrocyclic peptide targeting PCSK9 for cholesterol, showed up to 60.9% LDL cholesterol reduction in a Phase 2b trial. It received FDA approval in July 2026 as LIPFENDRA and represents the clearest clinical proof that oral macrocycles can deliver real pharmacology.
Beyond Merck, a growing crop of platform companies (Unnatural Products, Dayra Therapeutics, Encycle Therapeutics) are all racing to crack the oral macrocycle code. The competitive dynamics are converging around three design principles: reduce the molecule's polar surface area, increase structural rigidity through the ring shape, and use clever formulation tricks when chemistry alone falls short.
The fact that big pharma is now writing billion-dollar checks for discovery platforms, not just individual drugs, tells you where the field is heading. These aren't one-off asset bets; they're bets on entire chemistry engines.
What Analysts Are Saying
Wall Street's reaction has been constructive but measured. Analysts frame the Orbis deal as pipeline diversification, not a near-term revenue catalyst. That's fair; this is a discovery-stage collaboration, and any resulting drug is years away from generating sales.
But the strategic read is more interesting than the financial one. Novo is systematically building a toolkit for oral cardiometabolic medicine that goes well beyond semaglutide. If even one or two of these platform bets pay off, the company could own the oral cardiometabolic space the same way it currently dominates injectables.
The Bottom Line
Novo Nordisk didn't pay up to $1.4 billion because macrocycles are cool (though they are). It paid because the company that figures out how to reliably turn injectable medicines into pills will own the next decade of cardiometabolic treatment. Orbis's platform is unproven in humans, the targets are undisclosed, and the timeline is long. But if the chemistry works, this deal could look like a bargain in hindsight.
For now, it's the most expensive bet in biotech that nobody's talking about on a molecule that doesn't exist yet. Classic Novo: thinking five moves ahead while everyone else argues about last quarter's Wegovy scripts.
Clinical & Regulatory
5 min read
ALS Just Broke Another Heart. This Time It Was Novartis.
Novartis killed its ALS drug lifonebart after a Phase 2 trial missed every endpoint, adding to a decades-long streak of industry failures against one of neuroscience's most stubborn diseases. But the company's next move tells a different story.
